High-Dose Upadacitinib Therapy for Refractory Metastatic Crohn Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

High-Dose Upadacitinib Therapy for Refractory Metastatic Crohn Disease

Published:2024-07-01 Issue:7 Volume:160 Page:782
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Ebriani Joseph¹,Yoon Jaewon²,Friedman Sonia²,Dalal Rahul³⁴,French Maureen³⁵,Charrow Alexandra³⁶

Affiliation:

1. UCLA School of Medicine, Los Angeles, California

2. Department of Gastroenterology, Tufts University School of Medicine, Boston, Massachusetts

3. Harvard Medical School, Boston, Massachusetts

4. Department of Gastroenterology, Brigham and Women’s Hospital, Boston, Massachusetts

5. Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston

6. Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts

Abstract

This case report describes 2 patients with metastatic Crohn disease who were treated with upadacitinib.

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2819259/jamadermatology_ebriani_2024_lo_240005_1721149718.37965.pdf

Reference6 articles.

1. Dermatological manifestations in inflammatory bowel diseases.;Antonelli;J Clin Med,2021

2. Metastatic Crohn’s disease of the face.;Chen;J Am Acad Dermatol,1996

3. Metastatic Crohn’s disease: an approach to an uncommon but important cutaneous disorder.;Aberumand;Biomed Res Int,2017

4. Metastatic Crohn disease: clearance with metronidazole.;Abide;J Am Acad Dermatol,2011

5. P491 efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn’s disease.;Colombel;J Crohns Colitis,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP